Undifferentiated pleomorphic sarcoma of the breast with neoplastic fever: case report and genomic characterization
- PMID: 35501497
- PMCID: PMC10020307
- DOI: 10.1007/s00432-022-04000-6
Undifferentiated pleomorphic sarcoma of the breast with neoplastic fever: case report and genomic characterization
Abstract
Purpose: Primary breast sarcomas are extraordinary rare, in particular undifferentiated pleomorphic sarcoma (UPS). UPS with neoplastic fever (UPS-NF) of the breast has not been reported yet. Here, we present an extended UPS-NF of the breast including its comprehensive molecular workup.
Methods: A 58-year-old female presented with general malaise, fever spikes, weight loss, and a massively swollen left breast. C-reactive protein and blood leucocytes were significantly increased. However, repeated blood cultures and smears were all sterile. Histopathology of the abscess-forming tumor revealed an undifferentiated malignancy with numerous of tumor giant cells as well as spindle-shaped cells with nuclear pleomorphism and hyperchromasia. Immunohistochemistry demonstrated partial, patchy desmin staining and weak heterogonous neuron-specific enolase immunoreactivity of tumor cells, but a focal staining for Melan-A.
Results: Neither common melanoma driver mutations nor an ultraviolet mutational signature was detected by whole genome sequencing. Using FISH and RT-PCR we also excluded translocations characteristic for clear cell sarcoma. Thus, the diagnosis of inflammatory UPS-NF of the breast was considered highly probable. Despite a complete mastectomy, the tumor recurred after only three months. This recurrence was treated with a combination of ipilimumab and nivolumab based on the primary tumor's TPS score for PD-L1 of 30%. After an initial response, however, the tumor was progressive again.
Conclusion: We describe here the first case of UPS-NF of the breast, which shows great clinical and histopathologic resemblances to previously reported UPS-NF of other anatomic localizations.
Keywords: Breast cancer; High grade sarcoma; Neoplastic fever; Undifferentiated pleomorphic sarcoma.
© 2022. The Author(s).
Conflict of interest statement
TG has received speakers and/or advisory board honoraria from BMS, Sanofi-Genzyme, MSD, Novartis Pharma, Roche, Abbvie, Almirall, Janssen, Lilly, Pfizer, Pierre Fabre, Merck-Serono, outside the submitted work. LS has received speakers and/or advisory board honoraria from BMS, Sun-Pharma, MSD, and Novartis. JCB is receiving speaker’s bureau honoraria from Amgen, Pfizer, Merck-Serono and Sanofi-Genzyme, is a paid consultant/advisory board member for eTheRNA, Merck-Serono, Pfizer, 4SC and Sanofi-Genzyme. His group receives research grants from BMS, Merck-Serono, and Alcedis. All other authors declare that they have no conflict of interest.
Figures



Similar articles
-
Clinicopathological and genetic characterization of radiotherapy-induced undifferentiated pleomorphic sarcoma following breast cancer: a case series of three tumors and comprehensive literature review.Diagn Pathol. 2024 Aug 15;19(1):110. doi: 10.1186/s13000-024-01534-w. Diagn Pathol. 2024. PMID: 39143618 Free PMC article.
-
High prevalence of MiTF staining in undifferentiated pleomorphic sarcoma: caution in the use of melanocytic markers in sarcoma.Histopathology. 2017 Apr;70(5):734-745. doi: 10.1111/his.13139. Epub 2017 Feb 1. Histopathology. 2017. PMID: 27926791
-
BRAF mutation in 'sarcomas': a possible method to detect de-differentiated melanomas.Histopathology. 2014 Apr;64(5):639-46. doi: 10.1111/his.12305. Epub 2013 Dec 7. Histopathology. 2014. PMID: 24117833
-
Undifferentiated and dedifferentiated soft tissue neoplasms: Immunohistochemical surrogates for differential diagnosis.Semin Diagn Pathol. 2021 Nov;38(6):170-186. doi: 10.1053/j.semdp.2021.09.005. Epub 2021 Sep 29. Semin Diagn Pathol. 2021. PMID: 34602314 Review.
-
Undifferentiated pleomorphic sarcoma of the pancreas: a rare case report and literature review.World J Surg Oncol. 2022 Feb 27;20(1):55. doi: 10.1186/s12957-022-02525-1. World J Surg Oncol. 2022. PMID: 35220968 Free PMC article. Review.
Cited by
-
Clinicopathological and genetic characterization of radiotherapy-induced undifferentiated pleomorphic sarcoma following breast cancer: a case series of three tumors and comprehensive literature review.Diagn Pathol. 2024 Aug 15;19(1):110. doi: 10.1186/s13000-024-01534-w. Diagn Pathol. 2024. PMID: 39143618 Free PMC article.
-
Clinical perspectives and outcomes of the giant breast phyllodes tumor and sarcoma: a real-world retrospective study.BMC Cancer. 2023 Aug 28;23(1):801. doi: 10.1186/s12885-023-11279-2. BMC Cancer. 2023. PMID: 37635229 Free PMC article.
-
Primary Undifferentiated Pleomorphic Sarcoma of the Breast: A Case Report with Literature Review of Similar Cases.Iran J Pathol. 2024 Winter;19(1):118-125. doi: 10.30699/IJP.2023.2006411.3139. Epub 2023 Dec 29. Iran J Pathol. 2024. PMID: 38864088 Free PMC article.
-
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.J Cancer Res Clin Oncol. 2022 Dec;148(12):3537-3546. doi: 10.1007/s00432-022-04055-5. Epub 2022 May 26. J Cancer Res Clin Oncol. 2022. PMID: 35616728 Free PMC article.
-
Initial Imaging Findings of Breast Liposarcoma: A Case Report.Diagnostics (Basel). 2023 Jul 20;13(14):2428. doi: 10.3390/diagnostics13142428. Diagnostics (Basel). 2023. PMID: 37510172 Free PMC article.
References
-
- Agaimy A, Specht K, Stoehr R, Lorey T, Märkl B, Niedobitek G, Straub M, Hager T, Reis AC, Schilling B, Schneider-Stock R, Hartmann A, Mentzel T (2016) Metastatic malignant melanoma with complete loss of differentiation markers (undifferentiated/dedifferentiated melanoma): analysis of 14 patients emphasizing phenotypic plasticity and the value of molecular testing as surrogate diagnostic marker. Am J Surg Pathol 40(2):181–191 - PubMed
-
- D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, Streicher H (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19(3):416–426 - PMC - PubMed
-
- Ferreira I, Arends MJ, van der Weyden L, Adams DJ, Brenn T (2022) Primary de-differentiated, trans-differentiated and undifferentiated melanomas: overview of the clinicopathological, immunohistochemical and molecular spectrum. Histopathology 80(1):135–149 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials